Cigarettes with ultralow nicotine levels are now being called the game-changer in the fight against smoking. If you are having trouble in quitting smoking, then, it is for you, that soon the Biden White House is expected to formally propose a plan that will order cigarette nicotine levels to be reduced, reports The Washington Post. For now though, it has been a failure, as these cigarettes, also known as VLN cigarettes that stands for very low nicotine are only available in 5,100 stores in 26 states. This is a very small fraction of the overall market for cigarettes. The company that makes it, 22nd Century, is struggling not because of the low supply, but also from the advocates who have long believed slashing nicotine levels altogether.
Nicotine is a chemical that is produced naturally from tobacco that makes the cigarette and also keeps people hooked. While it is believed that it makes people alert, and get the "hit" to keep them going, it exposes the users to harmful substances, carcinogens, and increases the risk of heart disease, lung cancer, and other illness.
Ultralow-nicotine cigarettes, like the VLN brand, contain about 95% less nicotine than the regular cigarettes. The idea is quite simple: without the addictive grip of nicotine, smokers will find it easier to quit. Research too has shown some promise. For instance, the studies funded by the National Institute on Drug Abuse revealed that very low nicotine cigarettes reduced addiction potential significantly without having users to increase their smoking frequency. However, the problem is, why would anyone choose for a low-nicotine that does not make them feel the same way, when the high-nicotine cigarette is right next to it, making them feel the same way, with the same alertness, sold at the same price.
“It’s very hard to imagine someone actively choosing to continue to use a low-nicotine product for the same price when a high-nicotine product is right next to it,” said Eric Donny, a Wake Forest University School of Medicine nicotine researcher.
No wonder, the experiment with low nicotine product by Philip Morris' Next cigarettes in the 1980s and Vector Tobacco's Quest brand in the early 2000s, flopped.
The Food and Drug Administration (FDA) has supported the development of such products, even allowing VLN cigarettes to be marketed as lower-risk options. However, these products remain a niche market, available in only a fraction of U.S. stores.
Recently, the Biden administration has considered a bold step—mandating a dramatic reduction in nicotine levels for all cigarettes sold in the United States. Supporters believe this move could save millions of lives, while critics, including tobacco companies, warn of potential unintended consequences.
Resistance from Big Tobacco Companies: They could argue that slashing nicotine levels could backfire. Their claim is, smokers will turn to black markets or smoke more to satisfy their cravings, which may lead to greater exposure to harmful substances.
Consumer Reluctance: History is proof to the instances of smokers being hesitant to embrace the low-nicotine products.
Political Hurdle: It may face political roadblocks, as under the Trump administration, plans to cut nicotine were shelved.
Advocates believe that ultralow-nicotine cigarettes could be a game-changer, comparing them to decaf coffee or non-alcoholic beer—products that reduce harm while offering a similar experience.
Some experts warn that a black market for traditional cigarettes could undermine these efforts. They also stress the need for safer alternatives, such as vaping products, to support smokers transitioning away from traditional cigarettes.
Credit: Wikimedia Commons
Emmy-winning American actor Christina Applegate has in a shocking news revealed that she does not have multiple sclerosis (MS), despite continuing to experience debilitating symptoms since her 2021 diagnosis.
Applegate, 54, shared the news in an episode of her podcast MeSsy, co-hosted with fellow actor Jamie-Lynn Sigler and posted to YouTube on Tuesday.
“I’m back at square one – that I don’t know what’s going on with me,” she said through tears.
Applegate had gradually withdrawn from public life after her MS diagnosis in 2021, as she navigated the physical and emotional toll of the condition.
She has also become an advocate for MS awareness and chronicled her struggles in an emotional memoir published in March.
Also read: Why Multiple Sclerosis Increases Emotional Burden Among Women
Applegate recalled a visit to her doctor when she was told she did not have MS.
“She came into my room and said, ‘Congratulations, you don’t have MS,’” Applegate recalled through tears. “I was, like, not happy at all. Everybody else was so happy.”
Despite the news, Applegate said her symptoms have not improved.
“I haven’t gotten better. I still have to use wheelchairs when I go to the doctor’s office. I can’t walk from the car to the room. I’m still in this. Nothing magical happened when she said, ‘You don’t have MS.’ Nothing magical happened.”
Applegate also described feeling confused about her condition and the uncertainty surrounding her symptoms.
“It’s weird because I feel like I let everybody down. It’s this weird feeling of like I became this, you and I, the poster children for MS. Everything that I was doing, I had a fucking reason as to why my day sucked every day.
“And now I don’t have a reason. It’s very unnerving and it’s really confusing for me.”
Read More: Selena Gomez Says Vaping Changed Her Voice: How E-Cigarettes Affect Vocal Cords
According to the National Institute of Neurological Disorders and Stroke, multiple sclerosis is a chronic neurological condition that affects the central nervous system, including the brain, spinal cord and optic nerves.
MS is also an immune-mediated disease in which the immune system attacks myelin, the protective sheath surrounding nerve fibers. Damage to myelin can disrupt nerve signals, causing symptoms that vary from person to person.
These may include muscle weakness, fatigue, numbness, coordination problems, vision changes and memory difficulties.
MS is commonly diagnosed between the ages of 20 and 40, although it can develop earlier or later. There is no cure, but treatments can help manage symptoms and slow disease progression. Some people experience relapses with periods of improvement, while others develop progressively worsening disability.
Dr. Marwa Kaisey, an associate professor in the Department of Neurology at Cedars-Sinai Medical Center, joined Applegate and Sigler on the podcast to discuss MS misdiagnosis.
Kaisey said misdiagnoses are “fairly common” because there is no single test that can definitively confirm or rule out MS.
“We don’t have one single test for MS. It’s not like we have something like a pregnancy test that says, ‘Yes. You have it.’ ‘No. You don’t.’ It’s a list of criteria.”
Kaisey said nearly 20% of people diagnosed with MS may not actually have the disease, People.com reported.
“Almost one in five of these people who’d been told they had MS, some for decades, didn’t actually have it. And a majority of them were on medication to treat their MS,” she said.
MS diagnosis typically involves assessing symptoms, a neurological examination, magnetic resonance imaging (MRI) and, when appropriate, additional tests to rule out other conditions.
Because several disorders can cause similar symptoms, clinicians must evaluate the findings against established diagnostic criteria.
Credit: iStock
The UK is seeing a rise in COVID-19 infections ahead of winter, with the XFG variant, also known as Stratus, among the circulating strains.
Cases, hospital admissions and deaths have increased, while flu and respiratory syncytial virus (RSV) are also concerns heading into the colder months.
Latest UK Health Security Agency (UKHSA) data show around 2.46 COVID-19 hospital admissions per 100,000 people each week.
The UK recorded 3,942 confirmed cases in October so far, compared with 4,589 in September and 1,374 in August.
People aged 85 and older remain the most vulnerable, with almost 27 hospital admissions per 100,000 people, more than 10 times the national average. Around 13.5% of this age group tested positive, compared with 8.8% across all age groups.
COVID-19 deaths rose 46.4%, from 28 to 41, in the week ending October 2. Cases increased 13.5% in the week to October 7, according to UKHSA data.

Also read: XFG Variant In Spain: COVID-19 Cases Rise Amid Respiratory Infection Surge
A persistent cough, fever and sore throat are familiar COVID-19 symptoms. However, eye irritation and conjunctivitis may also signal infection, pharmacist Noel Wicks told The Mirror.
“The COVID-19 virus can enter the body through our eyes where it may cause symptoms.”
Wicks said conjunctivitis, which causes red, irritated and sometimes sticky eyes, can occur even without other COVID-19 symptoms.
“Clinical studies have demonstrated that conjunctivitis (red eye) is present in people who test positive for coronavirus, with rates of conjunctivitis ranging from 2% to over 14%, even if people don’t have any other COVID symptoms. In fact, conjunctivitis can be the first and/or the only symptom of COVID,” he said.
Research involving 6,308 people found that approximately 11% of COVID-19 patients experienced eye symptoms. These included conjunctivitis, dryness, redness, watering and itching.
Read More: XFG COVID Variant: What India Should Watch As Cases Rise In UK And France
According to Wicks, symptoms may include:
“These symptoms need to be tackled very quickly,” he said.
There is no established evidence that XFG causes eye symptoms more frequently than other COVID-19 variants. Allergies, bacterial infections and other viruses can also cause eye irritation, so these symptoms alone cannot confirm COVID-19.
Wicks recommends gently cleaning the eyes, avoiding rubbing them and temporarily stopping contact lens use and eye makeup until symptoms improve.
“Make sure to keep your eyes clean by washing them gently with a clean flannel to remove any crusts. Don’t rub your eyes as this can transfer infection from your hands to your eyes. Remove contact lenses and don’t wear eye makeup until the infection is better,” he advised.
Persistent irritation warrants advice from a healthcare professional. Eye pain, sensitivity to light or changes in vision require urgent medical assessment.
XFG, also known as Stratus, is a recombinant Omicron lineage formed when two Omicron sub-lineages combined. The World Health Organization classified it as a variant under monitoring in 2025 because of its growth advantage.
Although XFG carries mutations in its spike protein, studies suggest its ability to evade immunity differs only slightly from that of other JN.1 descendants.
There is no evidence that XFG causes more severe illness than other circulating Omicron variants. However, increased transmission can still raise hospital admissions by increasing the overall number of infections.
Credit: iStock
Fatty liver disease, which affects nearly 30% of adults worldwide, may comprise five biologically distinct subtypes, according to new research.
Researchers from the Mayo Clinic and Virginia Tech in the US found that each subtype may carry different risks of liver failure, cancer, heart disease and other serious complications.
The study, published in Nature Communications, suggests that metabolic dysfunction-associated steatotic liver disease (MASLD) can develop through different biological pathways. Some are closely linked to obesity and diabetes, while others appear to be driven by inherited genetic factors.
The findings suggest that genetic forms of the disease may progress to advanced liver damage even in people without typical metabolic risk factors.
Also read: NAFLD to MASLD: Experts Explain Why This Common Yet Dangerous Liver Condition Got Renamed
MASLD, previously known as nonalcoholic fatty liver disease, develops when excess fat accumulates in the liver. Many people experience no noticeable symptoms, allowing the condition to go undetected for years.
Although the disease does not always cause serious complications, it can progress to inflammation, scarring and permanent liver damage. In advanced cases, it may lead to cirrhosis, in which extensive scarring impairs liver function.
MASLD is a major contributor to cirrhosis, liver cancer and liver transplantation worldwide. Understanding why some patients develop severe complications while others do not is therefore an important research priority.
To investigate the differences, the researchers analyzed genetic sequencing results alongside detailed medical records from more than 4,600 patients with MASLD.
The data included liver enzyme measurements, body mass index, blood lipid levels and other indicators of metabolic health. The researchers also examined coexisting conditions, including diabetes, depression and sleep apnea.
Using computational models, they identified five groups of patients who shared distinct biological characteristics. The findings suggest that people with the same MASLD diagnosis may have different underlying disease processes and risks of complications.
“When clinical and genomic data are analyzed together at this scale, you begin to see patterns of disease progression that would otherwise remain hidden,” said Shulan Tian, Ph.D., co-senior author and a bioinformatician at Mayo Clinic. “Once you separate these subtypes, you can start to match treatments to the biology that's actually driving the disease.”
Read More: Lancet Study Shows Metabolic Liver Disease To Rise Over 38% By 2050: What’s Behind The Surge
The findings also suggest that the differences between MASLD subtypes extend beyond the liver.
Researchers identified associations between specific subtypes and conditions such as depression, sleep apnea and migraine. These links suggest that the biological processes underlying some forms of fatty liver disease may also be associated with health problems affecting other parts of the body.
However, the findings do not establish that MASLD directly causes these conditions.
Identifying distinct subtypes could eventually help doctors recognize high-risk patients earlier, improve screening and develop more personalized treatment strategies.
Eric Klee, a research and innovation leader at Mayo Clinic, said the approach could help researchers better understand disease progression and identify opportunities to intervene before severe damage occurs.
The team plans to evaluate the findings in larger and more diverse patient populations and investigate whether the subtypes respond differently to treatments, including GLP-1 receptor agonists.
If further studies validate the results, the research could help move MASLD care toward earlier intervention and treatments tailored to the biological processes driving each patient's disease.
© $2026 Times Horizon Private Limited